QUINOLINE DERIVATIVE FOR TREATMENT OF NEUROENDOCRINE TUMORS - CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD

Title:

QUINOLINE DERIVATIVE FOR TREATMENT OF NEUROENDOCRINE TUMORS

Document Type and Number:

WIPO Patent Application WO/2019/052520

Kind Code:

A1

Abstract:

A quinoline derivative 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine as represented by the following formula (I) for treatment of neuroendocrine tumors. Also disclosed is an application of the quinoline derivative in preparation of pharmaceutical compositions/medicaments for treatment of tumors, particularly neuroendocrine tumors.

More Like This:

JP2013224285	PHARMACEUTICAL
JP2005518377	Use of compounds to reduce the activity of hormone-sensitive lipase
JP2023515691	Inhibitors of EGFR, KRAS, BRAF, and other targets and their uses

Inventors:

ZHANG XIQUAN (CN)
WANG XUNQIANG (CN)
JIANG HAI (CN)
TIAN XIN (CN)
YANG LING (CN)

Application Number:

PCT/CN2018/105628

Publication Date:

March 21, 2019

Filing Date:

September 14, 2018

Export Citation:

Click for automatic bibliography generation Help

Assignee:

CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN)

International Classes:

A61K31/4709; A61P5/00; A61P5/14; A61P35/00

Domestic Patent References:

WO2008112407A1

2008-09-18

Foreign References:

CN105213394A	2016-01-06
CN102344438A	2012-02-08

Other References:

CHEN, RUIHUI: "Research Progress on Medullary Thyroid Carcinoma", GANSU MEDICAL JOURNAL, vol. 31, no. 5, 31 May 2012 (2012-05-31), XP009519962, DOI: 10.15975/j.cnki.gsyy.2012.05.036
See also references of EP 3682883A4

Attorney, Agent or Firm:

NANJING TIANHUA PATENT AGENT CO., LTD. (CN)

Download PDF:

View/Download PDF PDF Help

Previous Patent: BRD4 INHIBITOR

Next Patent: INTEGRATED TUBULAR REACTION DEVICE